NCT00184912|Completed
The Effect of Caffeine on Ischemic Preconditioning
Caffeine Reduces Acute Ischemic Preconditioning
Loading search results
Caffeine Reduces Acute Ischemic Preconditioning
Sponsor study identifier
interventional
24
1 country
1
Study Start
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
January 2006
Date type not reportedThis date has not been verified as actual or estimated.
Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption, we aimed to assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle. 24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or saline before a protocol for IP.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2006
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)September 16, 2005
Actual (reported)January 2006
Date type not reportedThis date has not been verified as actual or estimated.
Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.
Contact the study team to confirm eligibility.
Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
Nijmegen, Gelderland, 6500 HB, Netherlands
Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. doi: 10.1161/01.CIR.0000151612.02223.F2. Epub 2004 Dec 27.
Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol. 2006 Aug 15;48(4):700-7. doi: 10.1016/j.jacc.2006.04.083. Epub 2006 Jul 24.
Gerard Rongen, MD, Phd
Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology
First Submitted
September 12, 2005
First Posted
September 16, 2005
Study Start
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
January 2006
Date type not reportedThe Effects of Caffeine on Heart Rate and Heart Rate Variability
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This date has not been verified as actual or estimated.
Last Updated
November 29, 2006
Record last verified: 2006-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: